Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and managementJABBOUR, Elias; KANTARJIAN, Hagop.American journal of hematology. 2012, Vol 87, Num 11, pp 1038-1045, issn 0361-8609, 8 p.Article

Adult acute lymphoblastic leukemiaJABBOUR, Elias J; FADERL, Stefan; KANTARJIAN, Hagop M et al.Mayo Clinic proceedings. 2005, Vol 80, Num 11, pp 1517-1527, issn 0025-6196, 11 p.Article

Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase InhibitorsJABBOUR, Elias; CORTES, Jorge; KANTARJIAN, Hagop et al.Cancer. 2011, Vol 117, Num 5, pp 897-906, issn 0008-543X, 10 p.Article

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia : What Is the Optimal Strategy?JABBOUR, Elias; CORTES, Jorge E; KANTARJIAN, Hagop M et al.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 161-169, issn 0025-6196, 9 p.Article

Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic SyndromesKADIA, Tapan M; JABBOUR, Elias; KANTARJIAN, Hagop et al.Seminars in oncology. 2011, Vol 38, Num 5, pp 682-692, issn 0093-7754, 11 p.Article

Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?JABBOUR, Elias; KANTARJIAN, Hagop; CORTES, Jorge et al.Seminars in hematology. 2010, Vol 47, Num 4, pp 344-353, issn 0037-1963, 10 p.Article

Treatment selection after imatinib resistance in chronic myeloid leukemia : Hematological malignancy: coordinated by J. O. ArmitageJABBOUR, Elias; CORTES, Jorge; KANTARJIAN, Hagop et al.Targeted oncology. 2009, Vol 4, Num 1, pp 3-10, issn 1776-2596, 8 p.Article

Adult acute myeloid leukemiaJABBOUR, Elias J; ESTEY, Elihu; KANTARJIAN, Hagop M et al.Mayo Clinic proceedings. 2006, Vol 81, Num 2, pp 247-260, issn 0025-6196, 14 p.Article

Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid LeukemiaJABBOUR, Elias; SOVERINI, Simona.Seminars in hematology. 2009, Vol 46, Num 2, issn 0037-1963, S22-S26, SUP3Article

Molecular Monitoring in Chronic Myeloid Leukemia : Response to Tyrosine Kinase Inhibitors and Prognostic ImplicationsJABBOUR, Elias; CORTES, Jorge E; KANTARJIAN, Hagop M et al.Cancer. 2008, Vol 112, Num 10, pp 2112-2118, issn 0008-543X, 7 p.Article

Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid LeukemiaJABBOUR, Elias; CORTES, Jorge; RAVANDI, Farhad et al.Seminars in hematology. 2013, Vol 50, Num 4, pp 271-283, issn 0037-1963, 13 p.Article

Evolution of Decitabine Development : Accomplishments, Ongoing Investigations, and Future StrategiesJABBOUR, Elias; ISSA, Jean-Pierre; GARCIA-MANERO, Guillermo et al.Cancer. 2008, Vol 112, Num 11, pp 2341-2351, issn 0008-543X, 11 p.Article

Suboptimal Responses in Chronic Myeloid Leukemia: Implications and Management StrategiesJABBOUR, Elias; SAGLIO, Giuseppe; HUGHES, Timothy P et al.Cancer. 2012, Vol 118, Num 5, pp 1181-1191, issn 0008-543X, 11 p.Article

Red Blood Cell Transfusions and Iron Overload in the Treatment of Patients With Myelodysplastic SyndromesJABBOUR, Elias; KANTARJIAN, Hagop M; KOLLER, Charles et al.Cancer. 2008, Vol 112, Num 5, pp 1089-1095, issn 0008-543X, 7 p.Article

Current and emerging treatment options in chronic myeloid leukemiaJABBOUR, Elias; CORTES, Jorge E; GILES, Francis J et al.Cancer. 2007, Vol 109, Num 11, pp 2171-2181, issn 0008-543X, 11 p.Article

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemiaJABBOUR, Elias J; KANTARJLAN, Hagop; ELIASSON, Lina et al.American journal of hematology. 2012, Vol 87, Num 7, pp 687-691, issn 0361-8609, 5 p.Article

Current and Future Management Options for Myelodysplastic SyndromesBRYAN, Jeffrey; JABBOUR, Elias; PRESCOTT, Hillary et al.Drugs (Basel). 2010, Vol 70, Num 11, pp 1381-1394, issn 0012-6667, 14 p.Article

Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid LeukemiaJABBOUR, Elias; BRANFORD, Susan; SAGLIO, Giuseppe et al.Cancer. 2011, Vol 117, Num 9, pp 1800-1811, issn 0008-543X, 12 p.Article

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML TherapyKANTARJIAN, Hagop M; BACCARANI, Michele; JABBOUR, Elias et al.Clinical cancer research (Print). 2011, Vol 17, Num 7, pp 1674-1683, issn 1078-0432, 10 p.Article

Chronic Myeloid Leukemia: Mechanisms of Resistance and TreatmentJABBOUR, Elias; PARIKH, Sameer A; KANTARJIAN, Hagop et al.Hematology/oncology clinics of North America. 2011, Vol 25, Num 5, issn 0889-8588, 981-995, v [16 p.]Article

Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph⁺ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effectsJONES, Dan; CHEN, Su S; JABBOUR, Elias et al.Blood. 2010, Vol 115, Num 26, pp 5428-5429, issn 0006-4971, 2 p.Article

Comparison of thalidomide and lenalidomide as therapy for myelofibrosisJABBOUR, Elias; THOMAS, Deborah; KANTARJIAN, Hagop et al.Blood. 2011, Vol 118, Num 4, pp 899-902, issn 0006-4971, 4 p.Article

Central Nervous System Prophylaxis in Adults With Acute Lymphoblastic Leukemia: Current and Emerging TherapiesJABBOUR, Elias; THOMAS, Deborah; CORTES, Jorge et al.Cancer. 2010, Vol 116, Num 10, pp 2290-2300, issn 0008-543X, 11 p.Article

Thrombocytopenia in Patients With Myelodysplastic SyndromesBRYAN, Jeffrey; JABBOUR, Elias; PRESCOTT, Hillary et al.Seminars in hematology. 2010, Vol 47, Num 3, pp 274-280, issn 0037-1963, 7 p.Article

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assaysCAMERON YIN, C; CORTES, Jorge; GALBINCEA, John et al.Cancer science. 2010, Vol 101, Num 9, pp 2005-2010, issn 1347-9032, 6 p.Article